Our Take
Pharma giants are paying premium prices for late-stage assets rather than building internal pipelines.
Why it matters
Biotech valuations will climb as Big Pharma competes for proven drug candidates. Smaller companies with Phase 2+ assets in oncology or immunology now have maximum leverage.
Do this week
Biotech CFOs: Update acquisition comps before Q1 board meetings so you can price any inbound offers against the current market.
2026 M&A volume already exceeds 2025 totals
Pharmaceutical deal activity has accelerated sharply in early 2026, with transaction volume already surpassing last year's full-year totals (per PharmaVoice analysis). Eli Lilly and Gilead Sciences are leading the acquisition spree, targeting companies with cancer and autoimmune disease drug portfolios.
The buying focus centers on late-stage clinical assets rather than early discovery programs. Companies with Phase 2 and Phase 3 oncology trials are commanding premium valuations as acquirers compete for de-risked pipelines.
Patent cliffs force external growth strategies
Major pharmaceutical companies face revenue drops from expiring drug patents over the next three years. Rather than wait for internal R&D programs to mature, they are acquiring proven candidates with shorter paths to market approval.
This shift reflects pharma's acknowledgment that building comprehensive oncology and immunology capabilities internally takes too long. The time cost of developing expertise in complex disease areas makes acquisition the faster route to competitive positioning.
Lock advisory relationships before bidding wars intensify
Biotech companies should secure investment banking relationships now, before deal competition drives advisory fees higher. The current pace suggests acquisition multiples will climb throughout 2026 as buyers compete for limited late-stage assets.
For pharma corporate development teams, focus due diligence resources on regulatory pathway analysis rather than scientific validation. The bottleneck is approval timeline, not drug efficacy, given the focus on advanced-stage candidates.